Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically changed our world, country, communities, and families. There is controversy regarding risk factors for severe COVID-19 disease. It has been suggested that asthma and allergy are not highly represented as comorbid conditions associated with COVID-19.

Objective: Our aim was to extend our work in IL-13 biology to determine whether airway epithelial cell expression of 2 key mediators critical for SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2), are modulated by IL-13.

Methods: We determined effects of IL-13 treatment on ACE2 and TMPRSS2 expression ex vivo in primary airway epithelial cells from participants with and without type 2 asthma obtained by bronchoscopy. We also examined expression of ACE2 and TMPRSS2 in 2 data sets containing gene expression data from nasal and airway epithelial cells from children and adults with asthma and allergic rhinitis.

Results: IL-13 significantly reduced ACE2 and increased TMPRSS2 expression ex vivo in airway epithelial cells. In 2 independent data sets, ACE2 expression was significantly reduced and TMPRSS2 expression was significantly increased in the nasal and airway epithelial cells in type 2 asthma and allergic rhinitis. ACE2 expression was significantly negatively associated with type 2 cytokines, whereas TMPRSS2 expression was significantly positively associated with type 2 cytokines.

Conclusion: IL-13 modulates ACE2 and TMPRSS2 expression in airway epithelial cells in asthma and atopy. This deserves further study with regard to any effects that asthma and atopy may render in the setting of COVID-19 infection. (J Allergy Clin Immunol 2020;146:80-8.)

Key words: Asthma, IL-13, ACE2, TMPRSS2, nasal epithelial cells, airway epithelial cells, COVID-19, SARS-CoV-2, type 2 inflammation

Since its recognition in December 2019, the outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has generated strong concern among individuals presenting with underlying medical conditions. Individuals with chronic lung diseases or asthma are at higher risk for developing severe complications from COVID-19. Interestingly, among patients with allergy and asthma, there is controversy as to whether allergy and asthma represent comorbid conditions that increase risk for COVID-19. One study that reported 140 cases of COVID-19 in Wuhan, China, indicated no self-reported cases of asthma, allergic rhinitis, atopic dermatitis, or food allergy among infected patients. Moreover, a report by Dong et al suggested a low prevalence of asthma and allergy in pediatric cases and also found a low prevalence of rhinitis and atopic dermatitis. Lupia et al summarized clinical presentations of COVID-19 infection globally and reported a low prevalence of coexisting respiratory disease overall in patients with acute COVID-19 infection. However, a recent report from Seattle, Washington, describing 24 cases of acute lung injury associated with COVID-19 described 3 of 24 patients who had asthma and had been treated with oral corticosteroids within 1 week of presenting because of an asthma exacerbation. A recent publication from the COVID-19–Associated Hospitalization Surveillance Network describing 180 patients admitted to hospitals in the United States from March 1 to 22, 2020, reported that 17% of them carried the diagnosis of asthma. However, information regarding severity, medication requirements, and comorbid conditions of these patients is not currently known. Therefore, the controversy exists, as it is well known that viral infections exacerbate asthma.

For effective host cell entry, SARS-CoV-2 relies on 2 critical proteins, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2). Here, we demonstrate that IL-13, a cytokine associated with type 2 asthma, suppresses ACE2 expression and increases TMPRSS2 expression in airway epithelial cells from participants with type 2 asthma and atopy. On the basis of these findings, we hypothesized that type 2 cytokines modulate ACE2 and TMPRSS2 expression in the airway epithelial cell in asthma and atopy.
METHODS

Patient recruitment
Participants were recruited from the population in Tucson, Arizona, and the surrounding areas. Informed consent was obtained from each participant (18-65 years of age). Participants with asthma met the Global Initiative for Asthma criteria for mild and moderate asthma, including the presence of reversibility of airflow obstruction or airway responsiveness with a provocative concentration of methacholine resulting in a 20% decrease in FEV\(_1\) value (according to the National Heart, Lung, and Blood Institute and National Asthma Education and Prevention Program Expert Panel Report 3) not exceeding 8 mg/mL or less than 16 mg/mL if the participants were taking inhaled corticosteroids. 10 The presence of atopy was determined by using skin testing; peripheral eosinophil and fractional exhaled nitric oxide levels were measured. Healthy participants had no evidence of airflow obstruction and no history of pulmonary disease; the presence of atopy was not an exclusion. Exclusion criteria included an exacerbation of asthma within 4 weeks of enrollment. Exclusion criteria included any IL-4, IL-13, or IFN exposure.

Research bronchoscopy
Participants underwent bronchoscopy with endobronchial-protected brushing as previously described. 11 Brushing of the proximal airways to obtain bronchial epithelial cells was performed under direct visualization by using a separate protected cytologic brush for each pass, for a total of 8 passes. Participants were discharged when their FEV\(_1\) achieved 90% of the prebronchoscopy, postalbuterol value.

Human airway epithelial cell air-liquid interface experiments
Freshly isolated airway bronchial epithelial cells from endobronchial brushings were cultured with PneumaCult-EX Plus (StemCell Technologies, Vancouver, British Columbia, Canada). After reaching confluence, cells were trypsinized and seeded onto 12-mm-diameter collagen-coated polyester Transwell insert membranes (Corning, Lowell, Mass) at a concentration of 5 \times 10^4 per well. The cells were then cultured in the air-liquid interface by using PneumaCult–Air-Liquid Interface (StemCell Technologies) and allowed to differentiate for 2 weeks as previously described. 11 Cells were stimulated with 10 ng/mL of IL-13 (Peprotech, Rocky Hill, N.J) for 48 hours. Epithelial cells were collected for RT-PCR analysis of ACE2 and TMPRSS2 (see the section on PCR methods). Conditions were performed in triplicate with appropriate unexposed controls.

Quantitative reverse transcription PCR
Total mRNA was extracted according to instructions provided with the RNasy Plus Mini Kit (Qiagen), and cDNA was synthesized by using 1 μg of RNA (Applied Biosystems, Foster City, Calif). Real-time PCR was performed on a CFX96 Touch system (Bio-Rad, Hercules, Calif) by using TaqMan probes (Applied Biosystems) specific for PPIA, ACE2, and TMPRSS2. Fold changes for genes of interest were compared with those of the housekeeping gene, PPIA, and calculated by using the 2^−\Delta\Delta\text{Ct} method data presentation. 12

Gene expression analysis
Two data sets were downloaded from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/). The data set GSE19187 included gene expression data from a nasal epithelial cell brushing study of 38 children (11 healthy children, 14 children with isolated rhinitis, 7 children with rhinitis and controlled asthma, and 6 children with rhinitis and uncontrolled asthma) on a platform of the Affymetrix Human gene 1.0 ST Array. 13

The purpose of this study was to establish gene expression signatures of nasal brushings from children with dust mite allergic rhinitis as defined by clinical diagnoses and asthma control staging as determined by the Allergic Rhinitis and Its Impact on Asthma 14 clinical criteria and a positive result of skin prick testing to Dermatophagoides pteronyssinus and Dermatophagoides farinae. Diagnosis of controlled or uncontrolled asthma was based on the National Heart, Lung, and Blood Institute and the National Asthma Education and Prevention Program. Expert Panel Report 3 criteria. 13 Supervised learning and unsupervised clustering were used to predict the different subgroups of patients and define signaling pathways associated with rhinitis and asthma. These profiles were compared with those of primary cultures of human nasal epithelial cells stimulated with IL-4, IL-13, IFN-α, IFN-β, and IFN-γ following in vitro differentiation. For our analysis, we used baseline data obtained before any IL-4, IL-13, or IFN exposure.

The second data set, GSE4302, contained gene expression data that stemmed from an airway epithelial brushing study of 86 subjects (28 healthy subjects, 16 smokers, and 42 subjects with mild-to-moderate asthma) in which diagnosis of asthma was based on the National Heart, Lung, and Blood Institute and National Asthma Education and Prevention Program Expert Panel Report 3 criteria. 13 The data are on a platform of the Affymetrix Human Genome U133 Plus 2.0 Array (Thermo Fisher Scientific, Waltham, Mass). 16,19 In this study, participants underwent bronchoscopy with endobronchial brushing and biopsy. However, only epithelial gene expression data were included in the data set. Epithelial cell gene expression was determined by using microarray and PCR analysis. In a subset, epithelial cells were exposed to IL-13 and dexamethasone to further elucidate which genes were modulated by IL-13 and dexamethasone. Participants with a history of oral or inhaled steroid use in the past 4 weeks were excluded. For our analysis we evaluated baseline data obtained before exposure to IL-13 and/or dexamethasone.

Statistical analysis
Analysis of the ex vivo data was performed using a mixed-effects model with the subject as a random effect. We performed statistical analyses on ΔCt values (ΔCt=ΔCt\(_{\text{IL-13}}\)-ΔCt\(_{\text{B}}\)). Analysis on this scale (log of concentration) exhibits distributional characteristics that are more consistent with modeling assumptions (normal error constants within group variance) than the analyses for 2^−\Delta\Delta\text{Ct} that are commonly used. 12 The data were presented per the 2^−\Delta\Delta\text{Ct} once analysis was complete. We used linear mixed effect models to evaluate IL-13 treatment and asthma status on ΔCt values. The mixed model accommodates the nesting structure of participants within the asthma group and treatment replicates for each participant.

For analysis of the public databases, differences among the groups were analyzed by using the Wilcoxon rank sum test or Steel multiple comparison test, as appropriate. The trend among the groups was analyzed by using the Jonckheere-Terpstra test. For categorization of the type 2–low and type 2–high groups in the GSE19187 and GSE4302 data sets, respectively, unsupervised hierarchical clustering including values of 3 type 2 signature genes (calcium-activated chloride channel regulator 1 [CLCA1], peroxin [POSTN], and serpin family B member 2 [SERPINB2]) using the Euclidean metric with cusp ace linkage was performed as previously described. 17 Correlations between nonparametric data were undertaken by using the Spearman rank correlation test. Statistical significance was defined as a P value less than .05. All analyses were performed by using R version 3.6.1. software (The R Foundation: http://www.r-project.org/) or GraphPad Prism version 8.4.1 (GraphPad Software, San Diego, Calif).
RESULTS

IL-13 treatment suppresses ACE2 expression in airway epithelial cells ex vivo

Participant demographics for the ex vivo study are shown in Table I. The disease of the participants with asthma was mild to moderate in severity based on medication requirements with the patient requiring controller medication. The participants with asthma exhibited good to fair asthma control. All participants with and without asthma had a history of atopy based on their clinical history, presence of allergic rhinitis, and elevated fractional exhaled nitric oxide level. Total and allergen-specific IgE levels were not available for these participants.

IL-13 reduced ACE2 expression and increased TMPRSS2 expression in airway epithelial cells from both the asthma and nonasthma atopic groups (Fig 1). As it been suggested that ciclesonide may possess antiviral properties, we excluded the participant with asthma who used inhaled corticosteroids and repeated the analysis. We did not find significant differences in ACE2 and TMPRSS2 expression (data not shown).

Gene expression analysis

For the analysis of gene expression data, we used the publicly available results of 2 studies, GSE1918713 and GSE4302,16–19 as described in the Methods. For participant characteristics, see Tables E1 and E2 (in the Online Repository available at www.jacionline.org) and the original publications by Giovannini-Chami et al,13 Woodruff et al,16 Woodruff et al,17 Dougherty et al,18 and Park et al.19

ACE2 expression is lower in asthma and allergic rhinitis

In study GSE19187, nasal epithelial cells of participants with asthma and/or allergic rhinitis demonstrated lower ACE2 expression compared with that of healthy participants (Fig 2, A). Assessment of ACE2 expression by severity of symptoms (healthy, rhinitis without asthma, rhinitis with controlled asthma, and rhinitis with uncontrolled asthma) showed that participants with rhinitis and uncontrolled asthma demonstrated the lowest nasal epithelial cell ACE2 expression (the Jonckheere-Terpstra trend test, [Fig 2, B]). In addition, participants who were categorized as type 2–high on the basis of 3 gene signatures (CLCA1, POSTN, and SERPINB2), also demonstrated lower nasal epithelial ACE2 expression than did those categorized as belonging to the type 2–low and healthy control groups (Fig 2, C).

We next examined the association of nasal epithelial cell ACE2 expression with type 2 cytokines. IL-13, but not IL-4 and IL-5, was significantly negatively correlated with ACE2 expression (Fig 3, A–C). The type 2–driven genes CLCA1, POSTN, and SERPINB2 showed an inverse correlation with ACE2 expression (see Fig E1 in this article’s Online Repository at www.jacionline.org).

Airway epithelial cell ACE2 expression is lower in type 2–high participants with asthma

In data set GSE4302 containing airway epithelial cell mRNA, ACE2 expression was lower (albeit not significantly) in the participants with asthma than in the control participants (P = .097) (Fig 4, A). When participants with asthma were grouped into the categories type 2–high and type 2–low on the basis of 3 gene signature expressions,17 the type 2–high participants demonstrated lower expression of ACE2 than did the healthy participants, whereas the type 2–low participants demonstrated expression similar to that in healthy participants (Fig 4, B).

ACE2 expression in airway epithelial cells was correlated with type 2 cytokines, IL-4, IL-5, and IL-13 in participants with asthma (Fig 5, A–C). Furthermore, 2 type 2 cytokine–induced genes (ie, CLCA1 and SERPINB2, but not POSTN) were significantly negatively correlated with ACE2 expression when the group of those with asthma and the group of healthy participants were combined (see Fig E2 in this article’s Online Repository at www.jacionline.org).

TMPRSS2 gene expression is increased in allergic rhinitis and asthma

In data set GSE19187, the participants with asthma and/or allergic rhinitis demonstrated increased nasal epithelial cell expression of TMPRSS2 compared with the healthy participants, whether combined (Fig 6, A) or evaluated as separate groups (Fig 6, B). Moreover, the type 2–high participants demonstrated significantly higher expression of TMPRSS2, whereas the expression by type 2–low participants was similar to that by healthy participants (Fig 6, C). There was a significant correlation between nasal epithelial TMPRSS2 gene expression with CLCA1, POSTN, and SERPINB2, but not with IL-4, IL-5, or IL-13 (see Fig E3 in this article’s Online Repository at www.jacionline.org).

TMPRSS2 gene expression is positively correlated with type 2 cytokine–induced genes in asthma

Although gene expression of TMPRSS2 was not different between healthy participants and those with asthma (Fig 7, A), TMPRSS2 expression was higher (albeit not significantly) in type 2–high patients with asthma than in healthy participants (P = .86). There was no difference in TMPRSS2 expression between the healthy participants and the type 2–low participants with asthma (P = .84) (Fig 7, B).

In addition, a significant correlation between airway epithelial TMPRSS2 and IL-4 expression was present when both groups were combined, as well as for the group containing only subjects with asthma (see Fig E4 in this article’s Online Repository at www.jacionline.org). This relationship was not demonstrated for IL-5 and IL-13 (see Fig E4). Airway epithelial cell TMPRSS2 expression was significantly positively correlated with expression of CLCA1 and SERPINB2, but not with expression of POSTN when the asthma and control groups were combined (see Fig E5 in this article’s Online Repository at www.jacionline.org).

DISCUSSION

To our knowledge, this is the first report to show that IL-13 decreases ACE2 expression and increases TMPRSS2 expression in airway epithelial cells in asthma and atopy. These ex vivo observations are supported by interrogation of 2 public databases, which include children and adults and in which we have shown that ACE2 expression is reduced and TMPRSS2 expression is increased in type 2 asthma and rhinitis. In addition, ACE2 and TMPRSS2 expression are correlated with type 2 cytokines, although in opposite ways: ACE2 is inversely correlated with type 2 or type 2–driven genes, whereas TMPRSS2 expression is
positively correlated with type 2 or type 2–driven genes. These analyses are exploratory and provide a direction for future investigation.

Elucidation of the role of ACE2 in asthma is just beginning. The renin-angiotensin system is a critical component in regulating multiple tissue and organ functions, such as those of the cardiovascular system, kidney, lung, and liver, specifically by maintaining homeostasis of blood pressure, electrolyte balance, and inflammatory responses.21,22 Renin, a protease produced predominantly in the kidneys, cleaves angiotensinogen to generate angiotensin I (Ang I). Subsequently, angiotensin-converting enzyme (ACE) cleaves Ang I to produce angiotensin II (Ang II). Ang II is hydrolyzed by various angiotensinases, such as ACE2. ACE2 is a terminal carboxypeptidase and a type I transmembrane glycoprotein, as well as a potent negative regulator of the renin-angiotensin system. The imbalance in enzymatic activity of ACE/ACE2 has been suggested to be involved in pathogenesis in several diseases, including lung diseases.23

In asthma, ACE2 may have a role because of its anti-inflammatory nature and ability to inactivate Ang II and activate Ang1-7, which are the 2 counteractive systems strongly related to asthma. In an ovalbumin-challenged mouse model of type 2 asthma, Ang1-7 modulated ovalbumin-induced increases in total cell counts, eosinophils, lymphocytes, and neutrophils and decreased perivascular and peribronchial inflammation, fibrosis, and goblet cell hyper/metaplasia.24 These results support an important protective role of Ang1-7 in allergic asthma, as well as the role of ACE2 in reducing inflammation.24 Type 2 cytokines appear to reduce ACE2 expression, reducing the anti-inflammatory function of ACE2-generated Ang1-7.

ACE2 also has an additional function in relation to SARS-CoV-2 infection. The spike (S) protein of SARS-CoV-2 binds to ACE2 to mediate virus attachment to host cell membranes. Hoffmann et al9 demonstrated that host cell entry of SARS-CoV-2 depends on the SARS-CoV receptor ACE2 and can be blocked by a clinically proven inhibitor of the cellular serine protease TMPRSS2, which is used by SARS-CoV-2 for S protein priming. Inhibition of TMPRSS2 could be a therapeutic target in COVID-19. It has been shown that ACE2 is a host factor used in cell entry by 2 additional coronaviruses, SARS-CoV and human coronavirus NL63.25 TMPRSS2 has been reported to facilitate infection with human coronavirus 229E26 and Middle East respiratory syndrome–related coronavirus,27 H1N1,28,29 H3N2, and H7N9 influenza viruses.30,31 Taken together, both ACE2 and TMPRSS2 are important host factors for infection with many viruses, with some particularly relevant to asthma. We speculate whether the

| TABLE I. Participant characteristics for the ex vivo study |
|----------------------------------------------------------|
| Participant demographic characteristics                  |
|                                                         |
| Sex (n)                                                  |
| Females 1                                                |
| Males 2                                                  |
| Race (n)                                                 |
| White 2                                                  |
| Black 0                                                  |
| Asian 0                                                  |
| Hispanic 2                                               |
| Mean age, y, ± SD                                        |
| 31 ± 13                                                  |
| Mean body mass index, kg/m², ± SD                        |
| 25 ± 3                                                   |
| Age of onset (n)*                                        |
| >12 y N/A                                                |
| <12 y N/A                                                |
| Mean duration of asthma, y, ± SD                         |
| 33 ± 15                                                  |
| Mean Asthma Control Questionnaire score                  |
| 1.22 ± 0.76                                              |
| Exacerbations per year (n)                               |
| N/A                                                      |
| FENO concentration (ppb)                                 |
| 41 ± 30                                                  |
| 30 ± 8                                                   |
| Atopy (% positive)                                       |
| 100                                                      |
| Mean peripheral eosinophil level, %, ± SD                |
| 0.75 ± 0.83                                              |
| Mean peripheral eosinophil level, abs (× 10⁹/mm³), ± SD |
| 0.05 ± 0.05                                              |
| Mean peripheral neutrophil level, %, ± SD                |
| 57 ± 11                                                  |
| Mean peripheral neutrophil level, abs (× 10⁹/mm³), ± SD |
| 4 ± 2                                                    |
| Mean FVC, %, ± SD                                        |
| 105 ± 5                                                  |
| Mean FEV₁, %, ± SD                                       |
| 97 ± 10                                                  |
| Mean FEV₁/FVC ratio, %, ± SD                            |
| 76 ± 7                                                   |
| Mean PEFR, %, ± SD                                       |
| 77 ± 3                                                   |
| PC20 level (mg/mL)                                       |
| N/A                                                      |
| Medication (n)                                           |
| Short acting β-agonist N/A                              |
| Leukotriene modifier N/A                                |
| ICS N/A                                                  |
| Antihistamine N/A                                        |
| Combination therapy (ICS/LABA) N/A                       |
| Short-acting anticholinergic N/A                         |
| Intranasal corticosteroid 0 N/A                          |

| a.a, Absolute; FENO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; N/A, not available; PC20, provocative concentration of methacholine that resulted in a 20% decrease in the FEV₁. |
| Age of onset is not available for 1 participant. |
upregulation of TMPRSS2 gene expression in the upper and lower airways increases susceptibility of patients with asthma to infection by influenza.

The role of type 2 cytokines in ACE2 and TMPRSS2 expression is not clear. IL-4 and IL-13, both of which are type 2 cytokines relevant to asthma, reduce ACE2 expression in Vero E6 cells, a primate kidney epithelial cell line.\(^3\) We have shown similar effects by IL-13 in the upper and lower airways in human asthma and rhinitis. Although we evaluated gene expression, there are conflicting reports regarding the existence of ACE2 protein in the nasal epithelium. Hamming et al reported that ACE2 protein was present in the basal layer of the nonkeratinizing squamous epithelium but not present on the surface of nasal epithelial cells.\(^33\) Bertram et al noted ACE2 and TMPRSS2 immunostaining in sinus epithelium by using antigen retrieval methods.\(^34\) Furthermore, there are 2 forms of ACE2, full-length ACE2 and soluble ACE2, the latter which is shed from the full-length, membrane-bound protein and is considered as a potential therapy.\(^35\) In our study we report overall gene expression of ACE2 in nasal and airway epithelial cells to include the extracellular domain, but we do not report expression of membrane-bound and soluble forms. Although we speculate that type 2 cytokine stimulation may suppress ACE2 in the central and upper airway to reduce viral entry, evaluation of membrane-bound and soluble forms of ACE2 is the logical next step to determine the significance of this observation.

FIG 1. IL-13 exposure reduces ACE2 and increases TMPRSS2 expression in airway epithelial cells from participants with asthma and atopy. A, IL-13 exposure significantly reduces ACE2 expression in nonasthma atopic (mean = 1.27 [95% CI = 1.05-1.54] vs mean = 0.62 [95% CI 0.54-0.71]; *P = .0001) and asthmatic (mean = 0.95 [95% CI = 0.77-1.17] vs mean = 0.47 [95% CI = 0.27-0.82]; †P = .038) airway epithelial cells. B, IL-13 significantly increases TMPRSS2 expression in nonasthma atopic (mean = 0.69 [95% CI = 0.62-0.77] vs mean = 1.16 [95% CI = 1.10-1.23]; *P < .0001) and asthmatic (mean = 0.58 [95% CI 0.55-0.61] vs mean 1.28 [95% CI 1.15-1.44]; †P < .0001) airway epithelial cells.

FIG 2. ACE2 expression is reduced in nasal epithelial cells from type 2 (T2)-high participants with allergy. A, In data set GSE19187, participants with asthma and allergic rhinitis demonstrate lower expression of ACE2. *P = .0039. B, Participants with uncontrolled asthma (UA) demonstrate lower ACE2 expression than healthy controls do. *P = .0053 for the paired comparison; †P = .0035. C, When subtyped to T2-low and T2-high groups, T2-high participants demonstrate lower ACE2 expression than healthy controls do. *P = .0024 for paired comparison. Box plots show medians with interquartile ranges. CA, Rhinitis with controlled asthma; NA, rhinitis without asthma; UA, rhinitis with uncontrolled asthma.
FIG 3. ACE2 expression is significantly negatively correlated with IL-13 expression. The data from GSE19187 reveal no significant correlation between IL-4 and ACE2 (A) and between IL-5 and ACE2 (B). (C) IL-13 and ACE2 are significantly negatively correlated when all groups are combined. \( r_s \), Spearman rank correlation coefficient.

FIG 4. ACE2 expression is decreased in airway epithelial cells in type 2 (T2)-high asthma. A, In the gene expression data set from adult participants in GSE4302, ACE2 expression is reduced in all asthma participants compared with healthy participants, with a trend toward significance \((P = .097)\). B, Patients with T2-high asthma demonstrate lower airway epithelial ACE2 expression than healthy participants do. * \( P = .031 \) for the paired comparison. Box plots show medians with interquartile ranges.

FIG 5. Airway epithelial ACE2 is significantly negatively correlated with expression of IL-4, IL-5, and IL-13. Analysis of data set GSE4302 reveals a significant negative correlation of IL-4, IL-5, and IL-13 with ACE2 in the airway epithelial cells from participants with asthma and when asthma and healthy groups are combined. \( r_s \), Spearman rank correlation coefficient.
In addition, increased expression of TMPRSS2 could negate any protective effect of reduced ACE2 expression. Epidemiologic support for such assertion is suggestive, as studies from China have not identified asthma as a major risk factor for severe COVID-19\(^2,3\) and some reports from the United States have identified asthma as a risk factor for COVID-19\(^5,6\) whereas others have not.\(^36,37\) Additional data from both biologic and epidemiologic studies are warranted.

Whether inhaled or nasal corticosteroids are protective against SARS-CoV-2 infection merits comment, as it has been suggested that ciclesonide may possess antiviral properties owing to its ability to block viral replication.\(^20\) In our \textit{ex vivo} study, 1 of our participants with asthma used inhaled corticosteroids. We excluded this participant and repeated the analysis. We did not find significant differences in ACE2 and TMPRSS2 expression (data not shown). Participants whose nasal airway epithelial cell data were included in data set GSE19187 did not receive treatment with nasal corticosteroids for at least 1 month before enrollment. Similarly, participants whose airway epithelial cells are included in data set GSE4302 did not take inhaled or oral corticosteroids for 1 month before enrollment. Thus, the association of ACE2 and TMPRSS2 gene expression with type 2 cytokines, atopy, and type 2–high asthma are not dependent on the effect of corticosteroids in this analysis. This issue should be addressed in future investigation.

Our study has several strengths. Using airway epithelial cells from well-phenotyped atopic participants with and without asthma from our own laboratory, we have shown that IL-13 (1) suppresses ACE2 gene expression and (2) increases TMPRSS2 expression. We have observed similar results from 2 distinct data sets in children and adults with rhinitis and asthma. This approach adds robustness to the observation that IL-13 modulates the receptor system for COVID-19. Jackson et al have reported that underlying allergy and allergen exposure reduces the expression of ACE2.\(^38\) Our data extend their findings by (1) demonstrating contrasting changes in TMPRSS2 in response to IL-13 stimulation \textit{ex vivo} and (2) demonstrating that the effect of underlying allergy was type.

---

**FIG 6.** TMPRSS2 gene expression is higher in nasal epithelial cells from type 2 (T2)-high participants with allergy. In data set GSE19187, participants with asthma and/or allergic rhinitis demonstrate increased nasal epithelial expression of TMPRSS2 compared with that demonstrated by healthy participants regardless of whether the allergy and asthma groups were combined (*\(P < .0022\)) (A) or evaluated as separate groups (*\(P < .018\) for the paired comparison; \(1 \times 0.034\)) (B). C, The T2-high participants demonstrate significantly higher expression of TMPRSS2, whereas the expression of TMPRSS2 by T2-low participants is similar to that demonstrated by healthy participants. *\(P < .0012\) for the paired comparison. Box plots show medians with interquartile ranges. CA, Rhinitis with controlled asthma; NA, rhinitis and no asthma; UA, rhinitis with uncontrolled asthma.

**FIG 7.** TMPRSS2 expression is higher in the airway epithelial cells from type 2 (T2)-high asthma, with a trend toward significance. A, In the adult asthma study GSE4302, TMPRSS2 expression is not significantly different between healthy participants and participants with asthma (\(P = .13\)). B, TMPRSS2 expression tended to be higher in T2-high participants with asthma than in healthy participants (\(P = .086\)). Box plots show medians with interquartile ranges.
2–specific when unsupervised hierarchical clustering including type 2–induced genes was used. The limitations of our study include (1) the fact that our sample size for the *ex vivo* studies was small and (2) the fact that data from publicly available data sets do not include detailed clinical information.

In summary, we have provided evidence that type 2 inflammation suppresses expression of ACE2 and increases expression of TMPRSS2 in nasal and airway epithelial cells in asthma and atopy. These observations may provide a foundation to elucidate the relative role of these 2 mediators in cell entry and how type 2 cytokines modulate susceptibility to COVID-19.

We would like to acknowledge Pascal Barbry, PhD, and Prescott Woodruff, MD, for use of their data in databases GSE19187 and GSE4302, respectively. The authors would also like to acknowledge Ronald Schunk, MD, for his assistance with participant recruiting and bronchoscopy and Bianca Sierra for her assistance with *ex vivo* experiments.

Key messages:

- **11-13 decreases ACE2 expression and increases TMPRSS2 expression in bronchial epithelial cells *ex vivo***.
- **ACE2 and TMPRSS2 are modulated by type 2 inflammation in the upper and lower airways.**

REFERENCES

1. US Centers for Disease Control and Prevention. People who are at higher risk for severe illness. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Accessed April 11, 2020.

2. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [e-pub ahead of print]. Allergy. https://doi.org/10.1111/all.14238. Accessed April 11, 2020.

3. Dong X, Cao Y-Y, Lu X-X, Zhang J-J, Yu H, Yang X-Q, et al. Eleven faces of coronavirus disease 2019 [e-pub ahead of print]. Allergy. https://doi.org/10.1111/all.14289. Accessed April 11, 2020.

4. Lupia T, Scabini S, Mornese Pama S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: a new challenge. J Glob Antimicrob Resist 2020;21:22-7.

5. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007;104:15858-63.

6. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. J Allergy Clin Immunol 2012;130:1049-62.

7. Park S-W, Verhaeghe C, Nguyen LT, Barbeau R, Eisley CJ, Nakagami Y, et al. Distinct roles of FOXA2 and FOXA3 in allergic airway disease and asthma. Am J Respir Crit Care Med 2009;180:603-10.

8. Dougherty RH, Sidhu RS, Raman S, Bollberg DS, Caughey GH, et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol 2010;125:1046-53.e8.

9. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. A novel coronavirus SARS-CoV-2 causes respiratory disease with progression to acute respiratory distress syndrome in patients. Cell 2020;181:127–38.e6.

10. Giovannini-Chami L, Schneiter C, Moreilhon C, Chevalier B, Illie MI, Lebrigand K, et al. Allergic rhinitis and its impact on asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130:1049-62.

11. Kraft M, Adler KB, Ingram JL, Crews AL, Atkinson TP, Cairns CB, et al. Mycoplasma pneumoniae induces airway epithelial cell expression of MUC5AC in asthma. Eur Respir J 2008;31:43-6.

12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.

13. Giovannini-Chami L, Marcey B, Moreilhon C, Chevalier B, Illie MI, Lebrigand K, et al. Distinct epithelial gene expression phenotypes in childhood respiratory allergy. Eur Respir J 2012;39:1197-205.

14. Bourque G, Suleman MM, Egan AR, Dandekar T, Vidal M. The core of the connexome is encoded in the core of the genome. Cell 2016;166:809-23.

15. Roberts HR, Moreilhon C, Chevalier B, Illie MI, Lebrigand K, et al. Mucin gene expression and airway inflammation in atopic asthma. J Allergy Clin Immunol 2012;130:1049-62.
multiple sites in human respiratory and gastrointestinal tracts. PLoS One 2012;7: e35876.

35. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci 2020;134:543-5.

36. Asthma is absent among top Covid-19 risk factors, early data shows. The New York Times April 16, 2020. Available at: https://www.nytimes.com/2020/04/16/health/coronavirus-asthma-risk.html. Accessed May 2, 2020.

37. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? [e-pub ahead of print]. Lancet Respir Med https://doi.org/10.1016/S2213-2600(20)30167-3. Accessed May 1, 2020.

38. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2 [e-pub ahead of print]. J Allergy Clin Immunol https://doi.org/10.1016/j.jaci.2020.04.009. Accessed April 24, 2020.
REFERENCES

E1. Giovannini-Chami L, Marcet B, Moreillon C, Chevalier B, Illie MI, Lebrigand K, et al. Distinct epithelial gene expression phenotypes in childhood respiratory allergy. *Eur Respir J* 2012;39:1197-205.

E2. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit Care Med* 2009;180:388-95.
FIG E1. Expression of ACE2 and the type 2 (T2)-driven genes CLCA1 and SERPINB2 is significantly inversely correlated in nasal epithelial cells. Analysis of gene expression data from data set GSE19187 reveals inverse correlations between ACE2 with the T2-driven genes CLCA1 (A), POSTN (B), and SERPINB2 (C), with SERPINB2 trending toward significance. $r_s$ Spearman rank correlation coefficient.
FIG E2. ACE2 and type 2 (T2)-driven genes are inversely correlated in airway epithelial cells. In data set GSE4302 from adult participants with asthma and healthy controls, ACE2 is inversely correlated with CLCA1 (A), POSTN (B), and SERPINB2 (C) when asthma and control groups are combined, with POSTN trending toward significance. $r_s$: Spearman rank correlation coefficient.
FIG E3. TMPRSS2 expression is significantly correlated with type 2 (T2)-related genes in nasal epithelial cells. When the data set GSE19187 is used, significantly positive correlations between TMPRSS2 and the T2-driven signature genes CLCA1, POSTN, and SERPINB2 are present, but no such correlations are present with the T2 cytokines IL-4, IL-5, and IL-13. \( r_s \), Spearman rank correlation coefficient.
Airway epithelial TMPRSS2 expression is significantly positively correlated with IL-4 expression.

Data from GSE4302 revealed a significant correlation between airway epithelial TMPRSS2 expression and IL-4 when both groups are combined and for asthma only (A). B and C, This relationship is not demonstrated for IL-5 and IL-13. $r_s$, Spearman rank correlation coefficient.
Fig E5. *TMPRSS2* and type 2 (T2)-driven genes are significantly positively correlated in airway epithelial cells. In data set GSE4302, airway epithelial cell *TMPRSS2* expression is significantly positively correlated with expression of *CLCA1* (A) and *SERPINB2* (C) but not with expression of *POSTN* (B) when asthma and healthy control groups are combined. $r_s$, Spearman rank correlation coefficient.
### TABLE E1. Participants in GSE19187

| Characteristic                  | Control | Isolated rhinitis | Rhinitis with controlled asthma | Rhinitis with uncontrolled asthma |
|--------------------------------|---------|-------------------|---------------------------------|----------------------------------|
| Sample size (n)                | 11      | 14                | 7                               | 6                                |
| Dust mite allergy              | No      | Yes               | Yes                             | Yes                              |
| Mean age, y, ± SD              | 12 ± 3  | 11 ± 3            | 12 ± 3                          | 9 ± 1                            |
| T2-low-to-T2-high ratio        | 11:0    | 6:8               | 2:5                             | 1:5                              |

For additional information, please see Giovannini-Chami et al.\textsuperscript{E1} 72, Type 2.
| Characteristic       | Healthy | T2-low | T2-high |
|---------------------|---------|--------|---------|
| Sample size (n)     | 28      | 20     | 22      |
| Mean age, y, ± SD   | 36 ± 9  | 36 ± 11| 37 ± 12 |

For additional information, see Woodruff et al.\textsuperscript{[22]}

T2, Type 2.